results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech

3.7 percent compared to same period of the previous year, mainly due to the postponing of promotion activities for wholesales resulted from the spread of COVID-19 virus (COVID-19). Unit: Million Baht

of city shutdown measures both at home and abroad Which results in more economic activity to be carried out the indicators for private consumption have returned to the same level as the same period

its subsidiaries as details below: (Unit: Baht millions) For the period of three months Consolidated financial statement ended 30th June Apr 2018 - June 2018 Apr 2017 - June 2017 Change % Change Revenue

resulted in the Group’s Same-Store Sales Growth decreasing from +7.4% to -5.3% respectively. Franchise fee income increased from THB 15.2 Mn in the 3rd quarter of 2018 to THB 22.0 Mn in the same period of

follows: Performance Overview The Company and its subsidiaries had profit attributable to equity holders of the Company amounting to Baht 843.16 million, decreasing from the same period of the previous year

million baht from the same period last year. The Company’s performance for the 9-month period for 2018 showed a net loss of 37.4 million baht higher than the 9-month period for 2017 by 815.2 percent. The

profit THB 200.5 mn represents an increase of net profit margin 25.7% when compared to the previous quarter and increase of 33.1% when compared to the same period of last year regarding the change of cost

ending December 31, 2017 showed the net loss of Baht 131.23 million representing the decrease of 2.53% in net loss compared to net loss of Baht 134.64 million of the same period of the previous year. The

Unit : Million Baht Q1/18 Q1/17 Change Amount % Amount % Amount % Revenues from medical services 102.12 96.09 88.86 98.12 13.26 14.92 Other revenues 4.16 3.91 1.70 1.88 2.46 144.71 Total revenues 106.28